The companies plan to integrate Sequel’s twiist automated insulin delivery system with the Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world’s first and only one-year CGM.
In a news release, the companies say the integration would offer those with type 1 diabetes a new level of flexibility and personalization. The agreement provides the option of a one-year integrated system that could enhance diabetes management, the companies say. It offers more tools to manage care, leading to more improved glucose control, increased convenience and greater flexibility.
Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year.
“Sequel is committed to investing in innovations that empower people with diabetes with options in how they manage their diabetes,” said Sequel CEO and co-founder Dr. Alan Lotvin. “By partnering with Senseonics, a company pioneering long-duration CGM, we aim to deliver the flexibility people want to personalize their diabetes management on their terms.”
More about the technologies Sequel and Senseonics bring to the collaboration
Manchester, New Hampshire-based Sequel won FDA clearance for the twiist system powered by Tidepool just over one year ago. At the American Diabetes Association Scientific Sessions in June, Lotvin explained the unique advantages of the new system.
twiist, combined with the twiist Loop algorithm, directly measures the volume of insulin delivered with every microdose. It offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system utilizes sound waves that measure each pulse of insulin. This enables precision and helps understand exactly how much insulin the patient receives in a dose.
The system features iiSure technology, which includes four checkpoints to provide accurate delivery and alert users to blockages quickly. Cleared for ages six and up with type 1 diabetes, it offers a personalized way to manage the condition.
This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year.
Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems.
“This collaboration with Sequel marks a significant step forward in transforming diabetes care,” said Tim Goodnow, president and CEO of Senseonics. “People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management. The synergy of Eversense and twiist will provide people with diabetes our most recent innovations in advanced pump, algorithm, and sensor technologies to simplify diabetes management, providing users with an AID solution that unlocks the full experience of our year-long CGM technology.”
The analysts’ take
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang emphasized that this marks the first pump integration for Eversense. They note that Senseonics has been open about active discussions with manufacturers over a potential interoperable system.
“This marks the first step in enhancing the interoperability of Eversense beyond a standalone CGM though we expect limited commercial impact for SENS over the first few quarters since twiist is just being launched this quarter,” the analysts wrote. “We look forward to potential announcements of additional integration partnerships.”
They reaffirmed their “Neutral” rating for Senseonics.
